FDA clinical-studies narrative: widely propagated, low edge - treat it as a fade, not a fresh trade
The Opportunity
This is explicitly upstream-labelled edge decay: spreading lifecycle, low information edge, and direction set to FADE. That combination means the 'story' exists, but it is already in the bloodstream of Tier-1 and wire distribution, so any tradeable edge is likely exhausted. The practical read is that you should not pay a spread to chase a basket move on an FDA-themed cluster that is already being repeated across the ecosystem.
The Timing
The reason to AVOID is timing and propagation, not a lack of directional content. In Mixed 68 conditions with crosswind 78, crowded narratives tend to produce whipsaw and mean reversion rather than clean follow-through. What would change the assessment is a new, discrete regulator artefact (warning letter wave, guidance with an effective date, or a named high-profile CRL) that re-starts the clock; absent that, the upstream lifecycle call is that the edge is closing.
The Evidence
Upstream routing places this in propagation_monitor with an explicit FADE decision and decaying edge, driven by Tier-1 pickup in the originating bundle (including Reuters). The 6B evidence list for this cluster includes Tier-1 domains such as reuters.com and multiple PR-wire/trade domains, which is exactly the signature of 'broad awareness'.